RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
CUNEO A
Collezione AOU Novara
Items : 34
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study. in Hematological oncology / Hematol Oncol. 2024 Jan;42(1):e3216. doi: 10.1002/hon.3216. Epub 2023 Sep 29.
2024
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Molica S; Iannella E; Malgieri S; Gozzetti A; Gualberti G; Caira M; Finsinger P; Reda G; Coscia M; Vallisa D; Pane F; Cuneo A; Albano F; Zamprogna G; Trentin L; Mauro FR; Albi E; Gaidano G; Laurenti L; Sportoletti P; Chiarenza A;
Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. in EClinicalMedicine / EClinicalMedicine. 2023 Nov 15;65:102307. doi: 10.1016/j.eclinm.2023.102307. eCollection 2023 Nov.
2023
AOU Novara
AOU Città della Salute di Torino
Biderman B; Antic D; Angelopoulou M; Zuchnicka J; Yassin M; Yañez L; Yagci M; Xu Z; Wasik-Szczepanek E; Walewska R; Vukovic V; Vrachiolias G; von Tresckow J; Vitale C; Visentin A; Vassilakopoulos T; Tomic K; Tse E; Spacek M; Tadmor T; Abdelrahman Soliman DS; Smirnova S; Simkovic M; Shen Y; Schiwitza A; Schipani M; Daniel de Deus Santos M; Ruchlemer R; Rigolin GM; et alii...
Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report. in Hematological oncology / Hematol Oncol. 2023 Feb;41(1):201-204. doi: 10.1002/hon.3047. Epub 2022 Aug 19.
2023
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Novara
Marasca R; Foà R; Ballotta L; Moia R; Cuneo A; Chiurazzi F; Reda G; Gottardi D; Orsucci L; Maccaferri M; De Paoli L;
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
2023
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study. in Hematological oncology / Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1.
2023
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AO Alessandria
Laurenti L; Cuneo A; Foà R; Trentin L; Coscia M; Rigolin GM; Gattei V; Mattiello V; Sportoletti P; Gentile M; Scortechini I; Moia R; Catania G; Loseto G; Chiurazzi F; Malerba L; De Paolis MR; Angeletti I; Ferrari A; Giordano A; Baratè C; Leone MMA; Quaresmini G; Farina L; Fresa A; Piciocchi A; Vitale C; Reda G; Visentin A; et alii...
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. in American journal of hematology / Am J Hematol. 2023 Dec;98(12):1856-1868. doi: 10.1002/ajh.27093. Epub 2023 Sep 29.
2023
AOU Novara
AO Alessandria
AOU Città della Salute di Torino
Stamatopoulos K; Ghia P; Trentin L; Stavroyianni N; Vandenberghe E; Iyengar S; Coscia M; Rambaldi A; Montserrat E; Cuneo A; Vitale C; Segundo LYS; Pocali B; Yassin M; Wróbel T; Wasik-Szczepanek E; Van Der Spek E; van Gelder M; van Kampen R; Tonino SH; Te Raa D; Shrestha A; Saghumyan G; Mirás F; Reda G; Karlsson LK; Milosevic I; Del Poeta G; Gutwein O; et alii...
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.
2023
AO Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara
Cuneo A; Piciocchi A; Vignetti M; Fazi P; Foà R; Del Giudice I; De Propris MS; Nanni M; Molinari MC; Pietrasanta D; Mattiello V; Visentin A; Vitale C; Albano F; Neri A; De Novi LA; Tani M; Arcari A; Scarfò L; Giordano A; Gottardi D; Liberati AM; Galieni P; Patrizi VB; Deodato M; Musuraca G; Levato L; Marchetti M; Mannina D; et alii...
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. in American journal of hematology / Am J Hematol. 2022 May;97(5):E176-E180. doi: 10.1002/ajh.26502. Epub 2022 Feb 25.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara
Mauro FR; Trentin L; Foa' R; Tedeschi A; Gaidano G; Cuneo A; Coscia M; Guarente V; Noto A; Ielo C; Deodato M; Del Poeta G; Stelitano C; Moia R; Giordano A; Levato L; Rigolin GM; Gentile M; Murru R; De Paoli L; Laurenti L; Vitale C; Ciolli S; Chiarenza A; Sportoletti P; Frustaci AM; Visentin A; Reda G; Giannarelli D; et alii...
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. in Blood advances / Blood Adv. 2022 Mar 22;6(6):1742-1753. doi: 10.1182/bloodadvances.2021004821.
2022
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
Baccarani M; Foà R; Fazi P; Vignetti M; Cavo M; Sartor C; Paolini S; Granier M; Wang M; Zhu Z; Abbenante MC; Galieni P; Fabbiano F; Trappolini S; Tosi P; Bonifacio M; Martelli MP; D'Ardia S; Cuneo A; Tedeschi A; Frison L; Bocchia M; Vitale A; Candoni A; Selleri C; Simonetti F; Lunghi M; de Fabritiis P; Lemoli RM; et alii...
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study. in Haematologica / Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Novara
Cuneo A; Laurenti L; Ghia P; Foà R; Trentin L; Pompili M; Tedeschi A; Mauro FR; Del Poeta G; Scarfò L; Autore F; Tomasso A; Di Sevo D; Arena V; Deodato M; Ielo C; Frustaci AM; Piciocchi A; Rughini A; Cassin R; Albano F; Quaglia FM; Pennese E; Moia R; Gentile M; Murru R; Motta M; Coscia M; Visentin A; et alii...
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study. in Cancers / Cancers (Basel). 2022 Jan 27;14(3):654. doi: 10.3390/cancers14030654.
2022
AO Cuneo
AOU Novara
Petrini M; Stefoni V; Zinzani PL; Tisi MC; Kovalchuk S; Tani M; Pozzi S; Musuraca G; Rosignoli C; Arcari A; D'Alò F; Luzi D; Cantonetti M; Pane F; Gini G; Cuneo A; Visco C; Margiotta Casaluci G; Stefani PM; Casadei B; Patti C; Broccoli A; Argnani L;
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. in Blood advances / Blood Adv. 2022 Jan 11;6(1):327-338. doi: 10.1182/bloodadvances.2021005691.
2022
ASL Torino 5
ASL Biella
AO Cuneo
AOU Città della Salute di Torino
ASL Cuneo 1
AOU Novara
AO Alessandria
Bertù L; Ladetto M; Pilerci S; Pinto A; Ramadan S; Marchesi F; Cavo M; Visco C; Romano A; Coviello E; Merli F; Passamonti F; Krampera M; Corradini P; Candoni A; Conconi A; Tosi P; Lanza F; Venditti A; Selleri C; Vallisa D; Visani G; Gambacorti-Passerini C; La Barbera EO; Rigacci L; Armiento D; Cilloni D; Corso A; Cardinali V; et alii...
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AO Alessandria
AOU Novara
Foà R; Orsucci L; Penna G; Chiarenza A; Gattei V; Gottardi D; Derenzini E; Levato L; Gozzetti A; Olivieri J; Murru R; Sanna A; Gentile M; Baratè C; Leone M; Stefoni V; Tisi MC; Malerba L; Ibatici A; Marasca R; Chiurazzi F; Varettoni M; Del Poeta G; Marchetti M; Farina L; Giordano A; Re F; De Paoli L; Foglietta M; et alii...
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. in Cancers / Cancers (Basel). 2021 Jun 29;13(13):3240. doi: 10.3390/cancers13133240.
2021
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
Trentin L; Gentile G; Girmenia C; Martelli M; Gaidano G; Foà R; Cuneo A; Tedeschi A; Molica S; Coscia M; Noto A; Guarente V; Stelitano C; Del Poeta G; Giordano A; Rigolin GM; De Paoli L; Murru R; Gentile M; Levato L; Ielo C; Laurenti L; Ciolli S; Vitale C; Frustaci AM; Chiarenza A; Sportoletti P; Reda G; Visentin A; et alii...
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. in Blood / Blood. 2021 Jun 24;137(25):3507-3517. doi: 10.1182/blood.2020008201.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Boccadoro M; Mauro FR; Foà R; Tedeschi A; Scarfò L; Gaidano G; Trentin L; Cuneo A; Orsucci L; Reda G; Perutelli F; De Paoli L; Montalbano MC; Boccellato E; Gentile M; Rivela P; Marchetti M; Pennese E; Rigolin GM; Murru R; Laurenti L; Cassin R; Vassallo F; Visentin A; Zamprogna G; Schiattone L; Griggio V; Porrazzo M; Vitale C; et alii...
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study. in Leukemia / Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Sportoletti P; Laurenti L; Gattei V; Gaidano G; Polliack A; Foà R; Rossi D; Cuneo A; Di Raimondo F; Rigolin GM; Bomben R; Biagi A; Del Giudice I; Angeletti I; Rago A; Arrigo G; Vigna E; Botta C; Tripepi G; Fraticelli V; Zucchetto A; Scortechini I; Loseto G; Consoli U; Rossi FM; Pietrasanta D; Murru R; Chiarenza A; Condoluci A; et alii...
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.
2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AO Alessandria
AOU Novara
Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Piciocchi A; Nanni M; Raponi S; Ruocco V; Murru R; Della Starza I; De Propris MS; Del Giudice I; Chiarenza A; Laurenti L; Varettoni M; Ibatici A; Gentile M; Tani M; Musuraca G; Gottardi D; Zinzani PL; Molinari A; Gozzetti A; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. in Leukemia / Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Ghia P; Stamatopoulos K; Cuneo A; Montserrat E; Foà R; Yassin M; Coscia M; Rambaldi A; San Segundo LY; Visentin A; Vitale C; Wasik-Szczepanek E; Wróbel T; van Kampen R; Varettoni M; Tadmor T; Te Raa D; Tonino SH; van Gelder M; Van Der Spek E; Trentin L; Sportoletti P; Stanca O; Stavroyianni N; Špa?ek M; Šimkovi? M; Shrestha A; Saghumyan G; Ruchlemer R; et alii...
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group. in Hematological oncology / Hematol Oncol. 2021 Aug;39(3):326-335. doi: 10.1002/hon.2861. Epub 2021 Mar 26.
2021
ASL Asti
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Montillo M; Foà R; Cuneo A; Gentile M; Crea E; Marasca R; Marchetti M; Vignetti M; Mauro FR; Laurenti L; Quaglia FM; Pietrasanta D; Molinari AL; Sportoletti P; Paolini R; Varettoni M; Gaidano G; Murru R; Vitagliano O; Coscia M; Farina L; Cibien F; Zamprogna G; Reda G; Arena V; Visentin A; Piciocchi A; Cavazzini F; Rigolin GM; et alii...
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. in European journal of haematology / Eur J Haematol. 2021 Apr;106(4):493-499. doi: 10.1111/ejh.13573. Epub 2021 Jan 28.
2021
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Gentile M; Gattei V; Ferrarini M; Foà R; Trentin L; Polliack A; Gaidano G; Cuneo A; Di Raimondo F; Rossi D; Jaksic O; Monti P; Cutrona G; Bomben R; Neri A; Fronza G; Menichini P; Biagi A; Del Giudice I; Angeletti I; Rago A; Galimberti S; Cassin R; D'Arrigo G; Mendicino F; Martino EA; Vigna E; Al-Janazreh H; Zucchetto A; et alii...
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab. in Blood cancer journal / Blood Cancer J. 2020 Sep 16;10(9):92. doi: 10.1038/s41408-020-00358-3.
2020
AOU Città della Salute di Torino
AO Cuneo
AO Alessandria
AOU Novara
Gattei V; Morabito F; Ferrarini M; Gaidano G; Cuneo A; Foà R; Trentin L; Fronza G; Cutrona G; Di Raimondo F; Angeletti I; Bomben R; Neri A; D'Arrigo G; Tripepi G; Vitale C; Al-Janazreh H; Rossi FM; Zucchetto A; Scortechini I; Consoli U; Loseto G; Pietrasanta D; Bossio S; Moia R; Recchia AG; Lucia E; Mendicino F; Vigna E; et alii...
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. in Leukemia / Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
2020
AO Cuneo
AOU Città della Salute di Torino
AO Alessandria
AOU Novara
Foà R; Rambaldi A; Montserrat E; Rossi G; Stamatopoulos K; Coscia M; Stavroyianni N; Strugov V; Tam C; Zdrenghea M; Shah N; Shrestha A; Stanca O; Ortiz Pareja M; Papaioannou M; Rossi D; Kalashnikova O; Hakobyan Y; Doubek M; Enrico A; Dimou M; Andres M; Chiarenza A; Nikitin E; Dos Santos G; Barna G; Yassin M; Pocali B; Sportoletti P; et alii...
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. in The Lancet. Haematology / Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.
2020
AO Alessandria
ASL Biella
AOU Città della Salute di Torino
ASL Torino 5
AOU Novara
Grossi PA; Corradini P; Pagano L; Corrao G; Bertù L; Franchi M; Visco C; Rigacci L; Armiento D; Pane F; Oberti M; Zappasodi P; Galieni P; Fava C; Candoni A; Venditti A; Pinto A; Marchesi F; Musto P; Federici AB; Olivieri A; Gentile M; Bocchia M; Selleri C; Ortu La Barbera E; Ferrandina C; Di Renzo N; Luppi M; Scattolin AM; et alii...
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. in Cancer medicine / Cancer Med. 2020 Nov;9(22):8468-8479. doi: 10.1002/cam4.3470. Epub 2020 Sep 24.
2020
ASL Asti
AOU Città della Salute di Torino
ASL Vercelli
AO Cuneo
AOU Novara
Cucci R; Vignetti M; Foà R; Ghia P; Ferrarini I; Cimino G; Cavallari M; Medina Perez A; Mauro FR; de la Serna J; Coscia M; Di Raimondo F; Molica S; Farina L; Gaidano G; Doubek M; Ilariucci F; Tedeschi A; Marchetti M; Spacek M; Trentin L; Billio A; Ujjani CS; Roeker L; Orlandi EM; Shah NN; Schuster SJ; Pu JJ; Sehgal AR; et alii...
Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. in Haematologica / Haematologica. 2020 Jan 31;105(2):448-456. doi: 10.3324/haematol.2019.219550. Print 2020.
2020
AOU Città della Salute di Torino
AOU Novara
Cuneo A; Follenzi A; Poeta GD; Bertoni F; Lawless S; Thornton P; Mills K; Donaldson D; Weir P; Motta M; Laurenti L; Tedeschi A; Perbellini O; Coscia M; Marasca R; Rigolin GM; Chiarenza A; Visco C; Rossi FM; Bomben R; Cortelezzi A; Zaja F; Forconi F; Mauro FR; Giudice ID; Peroni D; Kodipad AA; Jabangwe C; Sagiraju S; et alii...
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease. in British journal of haematology / Br J Haematol. 2019 Apr;185(1):156-159. doi: 10.1111/bjh.15405. Epub 2018 May 22.
2019
AOU Novara
Raponi S; Del Giudice I; Ilari C; Cafforio L; Messina M; Cappelli LV; Bonina S; Piciocchi A; Marinelli M; Peragine N; Mariglia P; Mauro FR; Rigolin GM; Rossi F; Bomben R; Dal Bo M; Del Poeta G; Diop F; Favini C; Rossi D; Gaidano G; Cuneo A; Gattei V; Guarini A; Foá R;
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. in Leukemia & lymphoma / Leuk Lymphoma. 2018 Feb;59(2):423-433. doi: 10.1080/10428194.2017.1339872. Epub 2017 Jun 22.
2018
AOU Novara
Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R;
Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2018 Apr 1;29(4):966-972. doi: 10.1093/annonc/mdy021.
2018
AOU Novara
Raponi S; Del Giudice I; Marinelli M; Wang J; Cafforio L; Ilari C; Piciocchi A; Messina M; Bonina S; Tavolaro S; Bordyuh M; Mariglia P; Peragine N; Mauro FR; Chiaretti S; Molica S; Gentile M; Visentin A; Trentin L; Rigolin GM; Cuneo A; Diop F; Rossi D; Gaidano G; Guarini A; Rabadan R; Foà R;
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. in Blood / Blood. 2015 Oct 15;126(16):1921-4. doi: 10.1182/blood-2015-05-647925. Epub 2015 Aug 14.
2015
AOU Città della Salute di Torino
AOU Novara
Zinzani PL; Massaia M; Moreno C; Del Poeta G; Perbellini O; Marasca R; Neri A; Tedeschi A; Rigolin GM; Motta M; Coscia M; Vincelli I; Del Giudice I; Gentile M; Laurenti L; Forconi F; Zaja F; Cortelezzi A; Mauro FR; Morabito F; Visco C; Bulian P; Chiarenza A; Ghilardi G; Cerri M; De Paoli L; Terzi-di-Bergamo L; Rossi D; Montillo M; et alii...
Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. in Leukemia / Leukemia. 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. Epub 2013 Nov 13.
2014
AOU Città della Salute di Torino
AOU Novara
Neri A; Piciocchi A; Vignetti M; Morabito F; Fabris S; Mauro FR; Gobbi M; Cascavilla N; Angelucci E; Storti S; Orsucci L; Gritti G; Chiarenza A; Marasca R; Zaja F; Laurenti L; Reda G; Cuneo A; Vincenti D; Liberati AM; Sciumè M; Cortelezzi A; Rossi D; Giannarelli D; Guarini A; Foà R;
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. in Experimental hematology / Exp Hematol. 2014 Feb;42(2):126-36.e1. doi: 10.1016/j.exphem.2013.10.007. Epub 2013 Nov 6.
2014
AOU Novara
Maffei R; Fiorcari S; Bulgarelli J; Rizzotto L; Martinelli S; Rigolin GM; Debbia G; Castelli I; Bonacorsi G; Santachiara R; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R;